Accelerate Your Complex Biologic Development With Selexis® TranspoEase™ CLD Technology

Developing a difficult-to-express biotherapeutic may take up to 18 weeks, roughly 7-8 weeks longer than it takes to develop standard molecules. In many cases, traditional cell expression systems struggle to keep pace with the needs of mAbs, bispecifics, and advanced multi-specific antibodies. With cell line development (CLD) serving as the foundational step to manufacturing safe and effective therapies for patients, sponsors are facing mounting pressure to identify strategies that enable rapid cell expression of complex molecules to maintain competitive timelines.

In response to this critical need, KBI Biopharma designed a modular approach to CLD which delivers stable, scalable, and submission-ready results that adhere to sponsor timelines. In a recent webinar, the KBI team discussed their latest platform, TranspoEase , which has been proven to provide high titer and high stability cell line expression for complex proteins. Download the full article to read the expert insights of Séverine Fagète, PhD, Site Head & Vice President of Mammalian CLD, into the capabilities of TranspoEase to accommodate advanced biotherapeutics.